Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

Novonix (ASX:NVX) share price in a trading halt – now what?

Shares in lithium battery developer Novonix Ltd (ASX: NVX) finished in a trading halt yesterday after the company released its half-year results and also announced a proposed capital raising.

At the current price of $3.29, Novonix shares have returned more than 200% since December last year.

Why is Novonix raising capital?

Much of the hype surrounding Novonix recently has been the result of its announced partnership with Harper International. The partnership will support the development of new high-efficiency furnace technology for lithium-ion battery synthetic graphite material.

Under the agreement which will supply Samsung SDI, production will be ramped up to produce more than 2,000 tons per year using the new technology from Harper.

The required capital expenditure will partly be funded by the proceeds from the equity offering announced today, which will raise roughly $115 million through institutional and sophisticated investors.

The offer price has been set at $2.90 per share, representing an 11.9% discount to Novonix’s last closing price of $3.29.

Following the completion of the institutional placement, Novonix will also offer a non-underwritten share purchase plan to shareholders.

Additionally, subject to shareholder approval, the company will conduct placements of new shares to a select number of Novonix’s directors which will raise another ~$16.45 million.

The proceeds will be put towards increasing the scale of production for its Anode materials partnership to 10,000 tonnes per year, funding additional R&D in cathode and other battery technologies, and providing financial flexibility for potential international expansion.

Management commentary

Novonix’s Chairman, Tony Bellas, said: “The company remains well positioned as the only qualified producer in North America of high grade anode material suitable for lithium ion batteries for EVs and ESS. Importantly, the company is continuing to strengthen its position with key relationships across the industry such as Harper International to develop next generation furnace technology systems”.

My take

Novonix is undoubtedly an exciting growth story, but in an esoteric industry such as this, I find it hard to get a solid understanding of the technology.

Its market capitalisation of $1.1 billion seems fairly large for a company that just burnt through $12 million in cash in the last year with just $2 million in revenue. But then again, the valuation is about the future growth story, which seems to be a large opportunity if the company can execute its strategy well.

According to its Anode Materials phased growth plan, the company will ideally be producing roughly 150,000 tonnes in phase 3, which will be between 2026 and 2030. This would provide the production volume equivalent to 2.7 million electric vehicles per year – suddenly, the $1 billion market cap doesn’t seem too big based on a comparison such as this.

If you’re interested in learning more about the battery technology industry, check out this podcast episode which dives into the ACDC ETF and the industry more broadly:

Ep 95. Inside the ACDC ETF: A deep dive with Kanish Chugh

1 ASX Stock to Buy RIGHT NOW...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: